bevacizumab + cisplatin + erlotinib + pemetrexed

This is a four-drug combination regimen consisting of bevacizumab, cisplatin, erlotinib, and pemetrexed. It has been investigated primarily as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC), particularly in patients harboring activating EGFR mutations. The rationale for this combination is to integrate multiple mechanisms of action: - Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), thereby blocking angiogenesis and tumor blood supply. - Cisplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis in rapidly dividing cells. - Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that blocks EGFR signaling pathways involved in tumor proliferation. - Pemetrexed is an antifolate antimetabolite that disrupts folate-dependent metabolic processes essential for cell replication. Clinical studies have shown this quartet regimen to be tolerable and effective, with high response rates and promising progression-free survival in selected NSCLC populations[1][5]. Toxicities are generally manageable but can include gastrointestinal hemorrhage, skin rash, nausea, febrile neutropenia, anorexia, and fatigue[1][5].